Startup profile · funding coverage
Formation Bio
AI-native pharma company in-licensing and accelerating clinical-stage drug development.
Stage
growth
Status
private
Coverage
full
Why Formation Bio is interesting
Formation Bio pairs tech-enabled trial ops with drug in-licensing; a16z led a $372M Series D with Sequoia and Thrive among returning investors.
Key facts
- Series D (2024): $372M led by a16z (/fund/andreessen-horowitz) with Sequoia (/fund/sequoia) and Thrive Capital (/fund/thrive-capital) participation (PR Newswire)
- Sanofi also participated; company formerly known as TrialSpark (press)
Investors in our directory
Funds linked from Formation Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Formation Bio
Funding context and why this company shows up in venture coverage.
Formation Bio in-licenses clinical-stage drug programs and runs development with tech-enabled trial operations — combining pharma pipeline access with software-driven clinical and regulatory workflows.
Formation Bio's $372M Series D (2024) was led by Andreessen Horowitz (/fund/andreessen-horowitz). Sequoia (/fund/sequoia) and Thrive Capital (/fund/thrive-capital) also participated, along with Sanofi.
Formation Bio is at Series D based on its September 2024 $372M round.
Rather than building drugs from scratch, Formation Bio acquires or in-licenses mid-stage assets and uses operational software to compress timelines — a model that pairs pharma economics with venture-scale growth capital.
No. Formation Bio remains a private company.
Last updated: 2026-07-24